//fpnotebook.com/
Prostate Cancer Composite Risk
Aka: Prostate Cancer Composite Risk, Prostate Cancer Very Low Risk, Prostate Cancer Low Risk, Prostate Cancer Intermediate Risk, Prostate Cancer High Risk
- See Also
- Prostate Cancer
- Prostate Cancer Management
- Active Surveillance of Prostate Cancer
- Indications
- Prostate Cancer Management decision making tool
- Assessment of risk of Prostate Cancer related death based on Prostate Cancer grading, staging and PSA
- Used in conjunction with Charlson Comorbidity Index (Comorbidity-Adjusted Life Expectancy)
- Criteria: Required for the algorithm
- Prostate Cancer Staging
- Prostate Cancer Grading
- Prostate Specific Antigen
- Evaluation: Stage T1a to T2a
- Gleason Score 2-6
- PSA <10 ng/ml
- Very low risk
- Criteria for low risk (see below) not met
- Low risk
- Three or more core biopsies positive or
- Prostate Cancer involves >50% or more of sample or
- PSA Density =0.15
- PSA 10-20 ng/ml: Intermediate risk
- PSA >20 ng/ml: High risk
- Gleason Score 7
- PSA =20 ng/ml: Intermediate risk
- PSA >20 ng/ml: High risk
- Gleason Score 8-10
- High risk regardless of PSA
- Evaluation: Stage T2b or T2c
- Gleason Score 2-7
- PSA =20 ng/ml: Intermediate risk
- PSA >20 ng/ml: High risk
- Gleason Score 8-10
- High risk regardless of PSA
- Interpretation
- See Prostate Cancer Management
- Very low risk
- Prostate Cancer unlikely to cause serious morbidity or mortality within 20 years
- Low and moderate risk
- Prostate Cancer unlikely to cause serious morbidity or mortality within 10 years
- High Risk
- Prostate Cancer could result in serious morbidity or mortality within 5 years
- References
- Brawley (2018) Am Fam Physician 97(12): 798-805 [PubMed]
- Mohan (2011) Am Fam Physician 84(4): 413-20 [PubMed]